New variant of an imipenemase, IMP-32, in a Klebsiella pneumoniae from a fatal case of Thai patient  by Tribuddharat, C. et al.
e l of In
T
F
S
D
T
R
I
N
C
t
b
m
s
w
i
g
i
o
m
o
p
c
a
t
t
“
t
p
b
e
1
2
i
p
o
e
i
c
s
s
w
m
h436 15th ICID Abstracts / International Journa
ype: Poster Presentation
inal Abstract Number: 56.065
ession: Antibiotics
ate: Saturday, June 16, 2012
ime: 12:45-14:15
oom: Poster & Exhibition Area
ndividual-based simulations for malaria
. Tran ∗, M. Boni
Oxford University Clinical Research Unit, Ho Chi Minh, Ho Chi Minh
ity, Viet Nam
Background: As malaria eradication programs move forward
his decade, they will include a combination of vector control,
ednet use, anddeployment of various antimalarial therapies. Anti-
alarial treatment strategies must be evaluated to determine how
trongly they drive drug-resistance evolution. In order to evaluate
hich strategieshave thebest long-termoutcomes,wedesignedan
ndividual-based microsimulation model to compare such strate-
ies.
Methods: An individual-based epidemiological model was
mplemented in C++. The model keeps explicit track of (i) force
f infection according to parasite density in individual hosts, (ii)
ultiple infections in individual hosts, (iii) waning and acquisition
f non-speciﬁc immunity according to recent infection history, (iv)
harmacodynamics and pharmacokinetics of monotherapies and
ombination therapies, (v) heterogeneity in mosquito biting rates,
nd (iv) gametocytes.
Results: In accordance with previous modeling results, we ﬁnd
hatusingmultipleﬁrst-line therapies (MFT) results in slower resis-
ance evolution and fewer treatment failures than the status quo
cycling” strategies implemented in many countries. We ﬁnd that
his result also holds when using artemisinin combination thera-
ies.
Conclusion: Much work remains to be done to determine how
est to deploy ACTs to help with malaria eradication/elimination
fforts. These results, along with earlier work (Curtis and Otoo
986; Bonhoeffer et al 1997; Bergstrom et al 2004; Boni et al
008; Smith et al 2010) suggest that deploying multiple therapies
n the population at the same time is a more effective large-scale
opulation strategy than holding some drugs in reserve while rec-
mmending one as a primary ﬁrst-line therapy.
To determine the robustness of this result, future modeling
fforts will need to carefully parameterize drug pharmacokinet-
cs and pharmacodynamics, human patterns of drug use and drug
ompliance, and the local nature of malaria transmission. If the
uperiority ofMFT-strategies is robust to these variations, location-
peciﬁc models will need to be developed for countries or regions
ith the public health infrastructure to deploy andmanage an anti-
alarial MFT strategy.
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Background: Carbapenem-resistant Enterobacteriaceae has
become problematic recently worldwide. The ﬁrst carbapenem-
resistant Klebsiella pneumoniae from a provincial hospital near
Bangkok, Pranangklao Hospital, Nonthaburi, Thailand, was isolated
from a fatal case of 88 years old female patient. Identiﬁcation of a
resistant mechanism used by this isolate is very important for con-
trol andpreventionof possible spreadof this organismor its gene(s)
responsible for carbapenem resistance.
Methods: A sputum sample was obtained from a patient, and a
carbapenem-resistant K. pneumoniae was identiﬁed as a causative
agent of pneumonia. A modiﬁed Hodge test was positive indicating
a carbapenem hydrolyzing enzyme production. The gene ampli-
ﬁcations for blaKPC, blaOXA, blaVIM, and blaIMP by a PCR were
performed. An existence of class 1 integron element and resistance
gene cassettesweredeterminedby speciﬁcprimers for an integrase
gene and 5′CS and 3′CS primers. The ampliﬁed PCR products were
cloned and sequenced.
Results: The speciﬁc gene ampliﬁcation for blaIMPwas positive.
The 5′CS and 3′CS primers yielded two different DNA fragments
at sizes of 1,903 bp containing 3 cassettes; dfrA12, an unknown
open reading frame, and the aadA2 gene cassettes, and of 1,495 bp
containing 2 cassettes; a new imipenemase gene variant, blaIMP-
32, and an aac(6′) gene cassettes. The IMP-32 enzyme has only
one mutation (N175Y) different from IMP-1. The arrangement of
blaIMP-32- aac(6′) cassettes was very similar to the cassettes of
Pseudomonas aeruginosa carrying the blaIMP-14- aac(6′) cassettes
(1505 bp, accession number AY553332) identiﬁed 5 years earlier in
another hospital in Bangkok, Thailand.
Conclusion: We have identiﬁed the new imipenemase variant
encoded by blaIMP-32 gene. The new cassette was among 5 resis-
tance gene cassettes from two different class 1 integrons found
in a genome of K. pneumoniae. The identiﬁcation of new metallo-
beta-lactamasevariant in a genetic arrangement similar to integron
cassettes previously found in different species and different hospi-
tal has caught an attention for further investigation of possible gene
dissemination among hospitals in Thailand.
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